O
Olga Vasiljeva
Researcher at Jožef Stefan Institute
Publications - 74
Citations - 4208
Olga Vasiljeva is an academic researcher from Jožef Stefan Institute. The author has contributed to research in topics: Cathepsin B & Cancer. The author has an hindex of 24, co-authored 69 publications receiving 3670 citations. Previous affiliations of Olga Vasiljeva include University of Freiburg & Institute of Strength Physics and Materials Science SB RAS.
Papers
More filters
Journal ArticleDOI
Cysteine cathepsins: From structure, function and regulation to new frontiers
TL;DR: The view of cysteine cathepsins as lysosomal proteases is changing as there is now clear evidence of their localization in other cellular compartments, and some of the remarkable advances that have taken place in the past decade are presented.
Journal ArticleDOI
Emerging roles of cysteine cathepsins in disease and their potential as drug targets.
TL;DR: The current view on cathepsins as an emerging group of targets for several diseases and the development ofCathepsin K and S inhibitors for treatment of osteoporosis and various immune disorders are discussed.
Journal ArticleDOI
Ferri-liposomes as an MRI-visible drug-delivery system for targeting tumours and their microenvironment
Georgy Mikhaylov,Urša Mikac,A. A. Magaeva,V. I. Itin,E. P. Naiden,Ivan Psakhye,Ivan Psakhye,Liane Babes,Thomas Reinheckel,Christoph Peters,Robert Zeiser,Matthew Bogyo,Vito Turk,Sergey G. Psakhye,Boris Turk,Olga Vasiljeva +15 more
TL;DR: The ferri-liposomes were used to deliver a cathepsin protease inhibitor to a mammary tumour and its microenvironment in a mouse, which substantially reduced the size of the tumour compared with systemic delivery of the same drug.
Journal ArticleDOI
Tumor Cell–Derived and Macrophage-Derived Cathepsin B Promotes Progression and Lung Metastasis of Mammary Cancer
Olga Vasiljeva,Anna Papazoglou,Achim Krüger,Harald Brodoefel,Matvey Korovin,Jan M. Deussing,Nicole H. Augustin,Boye Schnack Nielsen,Kasper Almholt,Matthew Bogyo,Christoph Peters,Thomas Reinheckel +11 more
TL;DR: It is shown that mouse mammary tumor virus-polyoma middle T antigen (PyMT) transgenic mice deficient for the cysteine protease cathepsin B (CTSB) exhibited a significantly delayed onset and reduced growth rate of mammary cancers compared with wild-type PyMT mice.
Journal ArticleDOI
Tumor-specific activation of an EGFR-targeting probody enhances therapeutic index.
Luc R. Desnoyers,Olga Vasiljeva,Jennifer Richardson,Annie Yang,Elizabeth Menendez,Tony W. Liang,Chihunt Wong,Paul H. Bessette,Kathy Kamath,Stephen James Moore,Jason Gary Sagert,Daniel R. Hostetter,Fei Han,Jason Gee,Jeanne Grace Flandez,Kate Markham,Margaret Nguyen,Michael Krimm,Kenneth R. Wong,Shouchun Liu,Patrick S. Daugherty,James W. West,Henry B. Lowman +22 more
TL;DR: The development of a Probody that targets epidermal growth factor receptor (EGFR) only in the presence of tumor is reported, with markedly improved safety and increased half-life in nonhuman primates, enabling it to be dosed safely at much higher levels than cetuximab.